



Comprehensive Tumor Profiling


A better foundation for Molecular Intelligence

The Caris Molecular Intelligence[®] comprehensive tumor profiling approach to assess DNA, RNA and proteins reveals a molecular blueprint to guide more precise and individualized treatment decisions from among 60+ FDA-approved therapies.



DNA

Next-Generation Sequencing
(Mutations, Indels & Copy Number Alterations)



RNA

Whole Transcriptome Sequencing
(Fusions & Variant Transcripts)



Protein

Immunohistochemistry

Technical Specifications

Sufficient tumor must be present to complete all analysis. If you have any questions, please contact Customer Support at (888) 979-8669.

Technical Information	IHC	CISH	FISH
Sample Requirements <i>(see requisition for full details)</i>	1 unstained slide at 4µm thickness from FFPE block, with evaluable tumor present, per IHC test	1 unstained slide at 4µm thickness from FFPE block, with at least 20-100 evaluable tumor cells present, per CISH test	2 unstained slides at 4µm thickness from FFPE block, with at least 100 evaluable cells present and 10% tumor, per FISH test
Sensitivity/Specificity	>95%	>95%	>95%

Technical Information	Next-Generation Sequencing (DNA)	Whole Transcriptome Sequencing (RNA)
Sample Requirements	FFPE block or 10 unstained slides with a minimum of 20% malignant origin. Needle biopsy is also acceptable (4-6 cores).	FFPE block or 2-5 unstained slides with a minimum of 20% malignant origin. Needle biopsy is also acceptable (4-6 cores).
Tumor Enrichment (when necessary)	Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples	
Number of Genes	592 genes	~22,000 genes
Average Depth of Coverage (DNA) Average Read Count (RNA)	>750X	60 million
Positive Percent Agreement (PPA)	> 95% for base substitutions at ≥ 5% mutant allele frequency; > 95% for indels at ≥ 5% mutant allele frequency; >90% for copy number alterations (amplifications ≥ 6 copies)	>97%
Negative Percent Agreement (NPA)	>99%	>99%
Genomic Signatures	Microsatellite Instability (MSI), Tumor Mutational Burden (TMB)	-

Caris Molecular Intelligence® Associations List

The list below details the biomarkers assessed, technology platforms utilized and associated therapies or clinical trials. **Biomarkers and therapy associations may vary by the tumor type submitted.** The current and definitive list menu can be found online at www.CarisMolecularIntelligence.com/profiling-menu. *Individual assay results are always included with the final report.*

Agent	Biomarker	Platform
afatinib (assoc. in NSCLC only)	EGFR	NGS Mutation
afatinib + cetuximab (combination assoc. in NSCLC only)	EGFR T790M	NGS Mutation
alectinib, brigatinib, ceritinib	ALK	IHC; WTS Fusion
avelumab (assoc. in Bladder (non-urothelial) and Merkel cell only)	PD-L1	IHC
cabozantinib	MET	WTS Fusion
	RET	WTS Fusion
carboplatin, cisplatin, oxaliplatin	ATM	NGS Mutation
	BRCA1	NGS Mutation
	BRCA2	NGS Mutation
ceritinib	ALK	IHC; WTS Fusion
	ROS1 (assoc. in NSCLC only)	IHC; WTS Fusion
cetuximab, panitumumab ¹ (assoc. in CRC only)	BRAF	NGS Mutation
	KRAS	NGS Mutation
	NRAS	NGS Mutation
crizotinib	ALK	IHC; NGS Mutation; WTS Fusion
	MET (assoc. in Lung only)	NGS Mutation, CNA; WTS Fusion
	ROS1	WTS Fusion
dabrafenib, cobimetinib, vemurafenib, trametinib ¹	BRAF	NGS Mutation
dabrafenib + trametinib	BRAF	NGS Mutation (Anaplastic Thyroid and NSCLC only)
dacarbazine, temozolomide	MGMT-Methylation	Pyrosequencing
	IDH1 (assoc. in High Grade Glioma only)	NGS Mutation
doxorubicin, liposomal-doxorubicin, epirubicin	TOP2A	CISH (Breast only)
durvalumab (assoc. in NSCLC only)	PD-L1	IHC
encorafenib + binimetinib	BRAF	NGS Mutation (Melanoma only)
enzalutamide, bicalutamide	AR (assoc. in TNBC only)	IHC
erlotinib, gefitinib (assoc. in NSCLC only)	EGFR	NGS Mutation
	KRAS	NGS Mutation
	MET	NGS CNA

Agent	Biomarker	Platform
everolimus, temsirolimus	ER (assoc. in Breast only)	IHC
exemestane + everolimus, fulvestrant, palbociclib combination therapy	ER	IHC
	ESR1	NGS Mutation
hormone therapies ²	AR	IHC
	ER	IHC
	PR	IHC
imatinib	KIT	NGS Mutation
	PDGFRA	NGS Mutation
irinotecan + (cetuximab or panitumumab) + vemurafenib ¹ (assoc. in CRC only)	BRAF V600E	NGS Mutation
lapatinib, neratinib, pertuzumab, T-DM1	ERBB2 (Her2)	CISH; IHC; NGS CNA
larotrectinib	NTRK1/2/3	WTS Fusion; NGS Mutation (resistance)
immune checkpoint therapies ³	PD-L1	IHC
nivolumab (assoc. in CRC only), nivolumab + ipilimumab (assoc. in CRC only), pembrolizumab	MSI	NGS Mutation
	MMR Deficiency	IHC
niraparib, olaparib, rucaparib	ATM (assoc. in Prostate only)	NGS Mutation
	BRCA1	
	BRCA2	
osimertinib (assoc. in NSCLC only)	EGFR T790M, EGFR L858R, Exon 19del	NGS Mutation
palbociclib, abemaciclib, ribociclib (assoc. in Breast only)	ER	IHC
	ERBB2 (Her2)	IHC
sunitinib (assoc. in GIST only)	KIT	NGS Mutation
T-DM1 (assoc. in NSCLC only)	ERBB2 (HER2)	NGS Mutation
trastuzumab	ERBB2 (HER2)	CISH; IHC; NGS CNA, Mutation (NSCLC only)
vandetanib	RET	NGS Mutation; WTS Fusion

IHC: Immunohistochemistry **CISH:** Chromogenic *in situ* Hybridization **NGS:** Next-Generation Sequencing (DNA) **CNA:** Copy Number Alteration (DNA)

WTS: Whole Transcriptome Sequencing (RNA)

Note: in certain instances, some biomarkers included in MI Profile or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.

¹ In CRC, BRAF-targeted therapy is reported in combination with EGFR-targeted therapy.

² Hormone therapies may include: tamoxifen, toremifene, fulvestrant, letrozole, anastrozole, exemestane, megestrol acetate, leuprolide, goserelin, bicalutamide, flutamide, abiraterone, enzalutamide, triptorelin, abarelix, degarelix.

³ Immune checkpoint therapies may include: atezolizumab, nivolumab, pembrolizumab.

Biomarker Analysis by Tumor Type

The information below details the biomarkers analyzed by technology for the tumor type submitted. Before ordering testing services, please refer to the profile menu online (www.CarisMolecularIntelligence.com/profiling-menu) to view the most up-to-date listing of biomarkers that will be performed. Tests may vary if insufficient tumor samples are submitted.

MI Profile™					
Tumor Type	Immunohistochemistry (IHC)	Next-Generation Sequencing (NGS) <i>(see reverse for gene list)</i>		Whole Transcriptome Sequencing (WTS)	Other
		DNA	Genomic Signatures	RNA	
Bladder	MMR, PD-L1 (22c3)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Breast	AR, ER, Her2/Neu, MMR, PD-L1 (SP142), PR, PTEN	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	Her2, TOP2A (<i>Chromogenic in situ Hybridization</i>)
Cancer of Unknown Primary	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Cervical	ER, MMR, PD-L1 (22c3), PR	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Cholangiocarcinoma/Hepatobiliary	Her2/Neu, MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	Her2 (<i>Chromogenic in situ Hybridization</i>)
Colorectal and Small Intestinal	MMR, PD-L1 (SP142), PTEN	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Endometrial	ER, MMR, PD-L1 (SP142), PR, PTEN	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Esophageal Cancer	Her2/Neu, MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Gastric/GEJ	Her2/Neu, MMR, PD-L1 (22c3)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	Her2 (<i>Chromogenic in situ Hybridization</i>)
GIST	MMR, PD-L1 (SP142), PTEN	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Glioma	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	MGMT Methylation (<i>Pyrosequencing</i>)
Head & Neck	MMR, p16, PD-L1 (28-8)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	HPV (<i>Chromogenic in situ Hybridization</i>), reflex to confirm p16 result
Kidney	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Melanoma	MMR, PD-L1 (28-8)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Merkel Cell	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Neuroendocrine/Small Cell Lung	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Non-Small Cell Lung	ALK, MMR, PD-L1 (22c3), PTEN	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Ovarian	ER, MMR, PD-L1 (SP142), PR	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Pancreatic	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Prostate	AR, MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Salivary Gland	AR, Her2/Neu, MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Sarcoma	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Thyroid	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	
Uterine Serous	ER, Her2/Neu, MMR, PD-L1 (SP142), PR, PTEN	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	Her2 (<i>Chromogenic in situ Hybridization</i>)
Other Tumors	MMR, PD-L1 (SP142)	Mutation, CNA Analysis	MSI, TMB	Fusion Analysis	

MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2

For PD-L1 IHC testing, the antibody tested is listed above. For non-urothelial bladder cancers, PD-L1 clone SP142 is performed.

Next-Generation Sequencing Gene List

Next-Generation Sequencing – Genomic Stability Testing (DNA)									
Microsatellite Instability (MSI)					Tumor Mutational Burden (TMB)*				
Next-Generation Sequencing – Point Mutations and Indels (DNA)									
ABI1	BRD4	CRLF2	FOXO4	HOXC11	KLF4	MUC1	PAK3	RHOH	TAL2
ABL1	BTG1	DDB2	FSTL3	HOXC13	KLK2	MUTYH	PATZ1	RNF213	TBL1XR1
ACKR3	BTK	DDIT3	GATA1	HOXD11	LASP1	MYCL (MYCL1)	PAX8	RPL10	TCEA1
AKT1	C15orf65	DNM2	GATA2	HOXD13	LMO1	NBN	PDE4DIP	SEPT5	TCL1A
AMER1 (FAM123B)	CBLC	DNMT3A	GNA11	HRAS	LMO2	NDRG1	PHF6	SEPT6	TERT
AR	CD79B	EIF4A2	GPC3	IKBKE	MAFB	NKX2-1	PHOX2B	SFPO	TFE3
ARAF	CDH1	ELF4	HEY1	INHBA	MAX	NONO	PIK3CG	SLC45A3	TFPT
ATP2B3	CDK12	ELN	HIST1H3B	IRS2	MECOM	NOTCH1	PLAG1	SMARCA4	THRAP3
ATRX	CDKN2B	ERCC1	HIST1H4I	JUN	MED12	NRAS	PMS1	SOC51	TLX3
BCL11B	CDKN2C	ETV4	HLF	KAT6A (MYST3)	MKL1	NUMA1	POU5F1	SOX2	TMPRSS2
BCL2	CEBPA	FAM46C	HMG2P46	KAT6B	MLLT11	NUTM2B	PPP2R1A	SPOP	UBR5
BCL2L2	CHCHD7	FANCF	HNFI1A	KCNJ5	MN1	OLIG2	PRF1	SRC	VHL
BCOR	CNOT3	FEV	HOXA11	KDM5C	MPL	OMD	PRKDC	SSX1	WAS
BCORL1	COL1A1	FOXL2	HOXA13	KDM6A	MSN	P2RY8	RAD21	STAG2	ZBTB16
BRD3	COX6C	FOXO3	HOXA9	KDSR	MTCP1	PAFAH1B2	RECQL4	TAL1	ZRSR2

Next-Generation Sequencing – Point Mutations, Indels and Copy Number Alterations* (DNA)									
ABL2	BRCA1	CREB3L1	ETV1	GAS7	KMT2A (MLL)	MYCN	PER1	RUNX1	TFEB
ACSL3	BRCA2	CREB3L2	ETV5	GATA3	KMT2C (MLL3)	MYD88	PICALM	RUNX1T1	TFG
ACSL6	BRIP1	CREBBP	ETV6	GID4 (C17orf39)	KMT2D (MLL2)	MYH11	PIK3CA	SBDS	TFRC
ADGRA2	BUB1B	CRKL	EWSR1	GMP5	KNL1	MYH9	PIK3R1	SDC4	TGFBR2
AFDN	CACNA1D	CRTC1	EXT1	GNA13	KRAS	NACA	PIK3R2	SDHAF2	TLX1
AFF1	CALR	CRTC3	EXT2	GNAQ	KTN1	NCKIPSD	PIM1	SDHB	TNFAIP3
AFF3	CAMTA1	CSF1R	EZH2	GNA5	LCK	NCOA1	PML	SDHC	TNFRSF14
AFF4	CANT1	CSF3R	EZR	GOLGA5	LCP1	NCOA2	PMS2	SDHD	TNFRSF17
AKAP9	CARD11	CTCF	FANCA	GOPC	LGR5	NCOA4	POLE	SEPT9	TOP1
AKT2	CARS	CTLA4	FANCC	GPHN	LHFPL6	NF1	POT1	SET	TP53
AKT3	CASP8	CTNNA1	FANCD2	GRIN2A	LIFR	NF2	POU2AF1	SETBP1	TPM3
ALDH2	CBFA2T3	CTNNB1	FANCE	GSK3B	LPP	NFE2L2	PPARG	SETD2	TPM4
ALK	CBFB	CYLD	FANCG	H3F3A	LRIG3	NFIB	PRCC	SF3B1	TPR
APC	CBL	CYP2D6	FANCL	H3F3B	LRP1B	NFKB2	PRDM1	SH2B3	TRAF7
ARFRP1	CBLB	DAXX	FAS	HERPUD1	LYL1	NFKBIA	PRDM16	SH3GL1	TRIM26
ARHGAP26	CCDC6	DDR2	FBXO11	HGF	MAF	NIN	PRKAR1A	SLC34A2	TRIM27
ARHGGEF12	CCNB1IP1	DDX10	FBXW7	HIP1	MALT1	NOTCH2	PRRX1	SMAD2	TRIM33
ARID1A	CCND1	DDX5	FCRL4	HMGA1	MAML2	NPM1	PSIP1	SMAD4	TRIP11
ARID2	CCND2	DDX6	FGF10	HMGA2	MAP2K1 (MEK1)	NR4A3	PTCH1	SMARCB1	TRRAP
ARNT	CCND3	DEK	FGF14	HNRNPA2B1	MAP2K2 (MEK2)	NSD1	PTEN	SMARCE1	TSC1
ASPSR1	CCNE1	DICER1	FGF19	HOOK3	MAP2K4	NSD2	PTPN11	SMO	TSC2
ASXL1	CD274 (PDL1)	DOT1L	FGF23	HSP90AA1	MAP3K1	NSD3	PTPRC	SNX29	TSHR
ATF1	CD74	EBF1	FGF3	HSP90AB1	MCL1	NT5C2	RABEP1	SOX10	TTL
ATIC	CD79A	ECT2L	FGF4	IDH1	MDM2	NTRK1	RAC1	SPECC1	U2AF1
ATM	CDC73	EGFR	FGF6	IDH2	MDM4	NTRK2	RAD50	SPEN	USP6
ATP1A1	CDH11	ELK4	FGFR1	IGF1R	MDS2	NTRK3	RAD51	SRGAP3	VEGFA
ATR	CDK4	ELL	FGFR1OP	IKZF1	MEF2B	NUP214	RAD51B	SRSF2	VEGFB
AURKA	CDK6	EML4	FGFR2	IL2	MEN1	NUP93	RAF1	SRSF3	VTG1A
AURKB	CDK8	EMSY	FGFR3	IL21R	MET	NUP98	RALGDS	SS18	WDCP
AXIN1	CDKN1B	EP300	FGFR4	IL6ST	MITF	NUTM1	RANBP17	SS18L1	WIF1
AXL	CDKN2A	EPHA3	FH	IL7R	MLF1	PALB2	RAP1GDS1	STAT3	WISP3
BAP1	CDX2	EPHA5	FHIT	IRF4	MLH1	PAX3	RARA	STAT4	WRN
BARD1	CHEK1	EPHB1	FIP1L1	ITK	MLLT1	PAX5	RB1	STAT5B	WT1
BCL10	CHEK2	EPS15	FLCN	JAK1	MLLT10	PAX7	RBM15	STIL	WWTR1
BCL11A	CHIC2	ERBB2 (HER2/NEU)	FLI1	JAK2	MLLT3	PBRM1	REL	STK11	XPA
BCL2L11	CHN1	ERBB3 (HER3)	FLT1	JAK3	MLLT6	PBX1	RET	SUFU	XPC
BCL3	CIC	ERBB4 (HER4)	FLT3	JAZF1	MNX1	PCM1	RICTOR	SUZ12	XP01
BCL6	CIITA	ERC1	FLT4	KDM5A	MRE11	PCSK7	RII2	SYK	YWHAE
BCL7A	CLP1	ERCC2	FNBP1	KDR (VEGFR2)	MSH2	PDCD1 (PD1)	RNF43	TAF15	ZMYM2
BCL9	CLTC	ERCC3	FOXA1	KEAP1	MSH6	PDCD1LG2 (PDL2)	ROS1	TCF12	ZNF217
BCR	CLTCL1	ERCC4	FOXO1	KIAA1549	MSI2	PDGFB	RPL22	TCF3	ZNF331
BIRC3	CNBP	ERCC5	FOXP1	KIF5B	MTOR	PDGFRA	RPL5	TCF7L2	ZNF384
BLM	CNTRL	ERG	FUBP1	KIT	MYB	PDGFRB	RPN1	TET1	ZNF521
BMPR1A	COPB1	ESR1	FUS	KLHL6	MYC	PDK1	RPTOR	TET2	ZNF703
BRAF	CREB1								

Whole Transcriptome Sequencing – Genes most commonly associated with cancer listed below.

Fusions (RNA)								Variant Transcripts (RNA)	
ABL	BRD3	FGFR3	INSR	MYB	NUMBL	PRKCA	RSP03	AR-V7	
AKT3	BRD4	ERG	MAML2	NOTCH1	NUTM1	PRKCB	TERT		
ALK	EGFR	ESR1	MAST1	NOTCH2	PDGFRA	RAF1	TFE3	EGFR vIII	
ARHGAP26	EWSR1	ETV1	MAST2	NRG1	PDGFRB	RELA	TFEB		
AXL	FGR	ETV4	MET	NTRK1	PIK3CA	RET	THADA	MET Exon 14 Skipping	
BCR	FGFR1	ETV5	MSMB	NTRK2	PKN1	ROS1	TMPRSS2		
BRAF	FGFR2	ETV6	MUSK	NTRK3	PPARG	RSP02			

* Not available in New York State.

To order or learn more, visit www.Carismolecularintelligence.com.

US: 888.979.8669 | CustomerSupport@CarisLS.com – Intl: 00 41 21 533 53 00 | InternationalSupport@CarisLS.com

Caris Molecular Intelligence is a registered trademark of Caris MPI, Inc.

© 2019 Caris MPI, Inc. All rights reserved.

TN0276 v14 January 31, 2019

